MDXG vs ORGO
MDXG: MiMedx develops and distributes advanced wound care biologics including human placental allografts and expanding xenograft/collagen products to treat chronic and hard-to-heal wounds across surgical and clinical settings. ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance.
Side-by-side fundamentals
| Metric | MDXG | ORGO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.17 | $2.47 | |
| Market cap as of 2026-07-23 | $621M | $311M | |
| P/E as of 2026-07-23 | 20.23 | 114.52 | MDXG lower |
| PEG as of 2026-07-23 | n/a | -2.62 | |
| Net margin as of 2026-07-23 | +7.9% | +0.5% | MDXG higher |
| Gross margin as of 2026-07-23 | +81.0% | +72.9% | MDXG higher |
| Operating margin as of 2026-07-23 | +10.2% | +0.5% | MDXG higher |
| ROE as of 2026-07-23 | +12.9% | +0.7% | MDXG higher |
| ROA as of 2026-07-23 | +9.7% | +0.5% | MDXG higher |
| Debt / equity as of 2026-07-23 | 0.07 | 0.03 | ORGO lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.5% | +12.2% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +16.1% | +7.8% | MDXG higher |
| Beta as of 2026-07-23 | 1.47 | 1.34 | |
| 1-year return as of 2026-07-22 close | -35.0% | -48.8% | MDXG higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.